(MENAFN- GlobeNewsWire - Nasdaq) The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6.10%. Growth is driven by rising cancer cases and advancements in pain management, including medical cannabis. Key players include Eli Lilly, Pfizer, and Johnson & Johnson.

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Cancer Pain Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering.
The cancer pain market attained a value of USD 6.53 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 6.10%, to reach USD 11.81 Billion by 2034.

The market report covers 8 major markets poised to witness significant growth in upcoming years. The region-based segmentation of the market includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. North America dominates the market which can be attributed to the rising geriatric population, the presence of an advanced healthcare system, and the increased prevalence of cancer in the region.
The severity of pain can differ depending on factors such as the type of cancer and its stage. The rising prevalence of cancer necessitates the need for effective therapeutics to manage cancer pain. With the global burden of new cancer cases predicted to reach approximately 30 million by 2040, the cancer pain market demand is anticipated to surge in the forecast period.
The increased impetus for research activities to address the growing need for cancer pain treatment solutions has bolstered market growth. Intensive research efforts are paving the way for potential therapeutics. According to a study published in BMJ Supportive & Palliative Care in May 2023, medical cannabis was revealed to be safe and effective for treating cancer-related pain. Further, the use of medical cannabis reduced the use of opioids and other pain medications by almost 32%. Thus, the introduction of such products in cancer patients' pain regimens is likely to augment the cancer pain market growth.
The market is also driven by the rising healthcare expenditure to treat cancer-associated pain as well as various initiatives and programs launched by the government to raise awareness regarding the condition. Moreover, the rising geriatric population with increased susceptibility to cancer pain will also help in the market growth.

Key Queries Solved in the Cancer Pain Market Report

• How will the market landscape evolve in the coming years?
• What are the major market trends influencing the market?
• What are the major drivers, opportunities, and restraints in the market?
• Which country is poised to lead the market share in the forecast period?
• Which country is expected to experience expedited growth during the forecast period?
• How do factors such as the rising prevalence of cancer impact market growth?
• What are the different types of cancer pain treatments available in the market?
• What are the latest advancements in cancer pain drug research and development?
• What were the major drug approvals to manage cancer pain during the historical period?
• Which segment has the major impact on the cancer pain market size?
• What investments and funding are driving research and development in the market?
• What are the key strategies adopted by leading pharmaceutical companies to gain market share?
• How are partnerships, collaborations, and mergers & acquisitions shaping the market dynamics?

Key Attributes:

Report Attribute	Details
No. of Pages	400
Forecast Period	2025 - 2034
Estimated Market Value (USD) in 2025	$6.53 Billion
Forecasted Market Value (USD) by 2034	$11.81 Billion
Compound Annual Growth Rate	6.1%
Regions Covered	Global

Cancer Pain Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

• Eli Lilly
• Hisamitsu Pharmaceutical Co., Inc
• Aoxing Pharmaceutical Company, Inc
• Grunenthal Pharma Gmbh & Co. Kg
• Pfizer Inc.,
• Biodelivery Sciences International, Inc
• Orexo Ab
• Johnson And Johnson
• Medtronic Plc
• Novartis Ag
• Glaxo Smithkline Plc

Cancer Pain Market Segmentation
Market Breakup by Drug Type

• Opioids
• Fentanyl
• Morphine
• Others
• Non-Opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drug
• Nerve Blockers

Market Breakup by Indication Type

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Market Breakup by Treatment Type

• Immunotherapy
• Chemotherapy
• Targeted Therapy
• Hormonal Therapy

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Cancer Pain Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN23072025004107003653ID1109835666